Are There Benefits in Adding Catechol-O Methyltransferase Inhibitors in the Pharmacotherapy of Parkinson’s Disease Patients? A Systematic Review
Authors:
- 13 June 2018
- journal article
- review article
- Published by SAGE Publications in Journal of Parkinson’s Disease
- Vol. 8 (2) , 217-231
Abstract
Background: A qualified consensus suggests that a combination of levodopa with a peripherally acting dopa decarboxylase inhibitor continues to present the gold standard treatment of Parkinson’s disease (PD). However, as the disease progresses the theKeywords
This publication has 124 references indexed in Scilit:
- Therapeutic prospects for Parkinson diseaseAnnals of Neurology, 2013
- Clinical Approach to Parkinson's Disease: Features, Diagnosis, and Principles of ManagementCold Spring Harbor Perspectives in Medicine, 2012
- Gene–Environment Interactions in Parkinson's Disease: The Importance of Animal ModelingClinical Pharmacology & Therapeutics, 2010
- The Impact of Levodopa on Quality of Life in Patients With Parkinson DiseaseThe Neurologist, 2010
- Maladaptive striatal plasticity in l-DOPA-induced dyskinesia2010
- Crystal structures of the Apo and Holo form of rat catechol-O-methyltransferaseJournal of Structural Biology, 2009
- Levodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatmentPostgraduate Medical Journal, 2007
- Diagnosis and treatment of Parkinson disease: molecules to medicineJournal of Clinical Investigation, 2006
- Contrasting effects of peripheral decarboxylase inhibitors on plasma activity of aromatic-L-amino acid decarboxylase and semicarbazide-sensitive amine oxidase in Parkinson's diseaseLife Sciences, 1995
- 3-0-Methyldopa uptake and inhibition of L-dopa at the blood-brain barrierLife Sciences, 1975